Ken Griffin Verona Pharma PLC Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$11.48 - $17.02 $1.41 Million - $2.1 Million	123,100 Added 343.85%	158,900 $2.3 Million
Q1 2024 May 15, 2024	SELL	$15.3 - $20.24 $55,080 - $72,864	-3,600 Reduced 9.14%	35,800 $576,000
Q4 2023 Feb 14, 2024	BUY	$11.94 - $20.47 $1,194 - $2,047	100 Added 0.25%	39,400 $783,000
Q3 2023 Nov 14, 2023	SELL	$16.3 - $22.09 $96,170 - $130,331	-5,900 Reduced 13.05%	39,300 $640,000
Q2 2023 Aug 14, 2023	BUY	$19.41 - $23.43 $436,725 - $527,175	22,500 Added 99.12%	45,200 $955,000
Q1 2023 May 15, 2023	SELL	$18.06 - $25.27 $301,602 - $422,009	-16,700 Reduced 42.39%	22,700 $455,000
Q4 2022 Feb 14, 2023	BUY	$9.84 - $26.13 $387,696 - $1.03 Million	39,400 New	39,400 $1.03 Million

137

66.7M

495K

486K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $1.65B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.